Gene: ADGRL3

23284
CIRL3|CL3|LEC3|LPHN3
adhesion G protein-coupled receptor L3
protein-coding
4q13.1
Ensembl:ENSG00000150471 MIM:616417 Vega:OTTHUMG00000160690 UniprotKB:Q9HAR2
NG_033950.2
SNP Mapped
1   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.628e-1 (AD)  5.509e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6551640chr4:61653103 (GRCh38.p7)T>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0072971,6-diaminohexane"ADGRL3 gene modified form results in increased abundance of 1,6-diaminohexane"25445006
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ADGRL3 mRNA"19114083
C0065512-amino-2-methyl-1-propanol2-amino-2-methyl-1-propanol results in decreased expression of ADGRL3 mRNA25088246
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of ADGRL3 mRNA21298039
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ADGRL3 mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of ADGRL3 mRNA24449571
D001151ArsenicArsenic results in decreased expression of ADGRL3 mRNA19654921
C547126AZM551248AZM551248 results in decreased expression of ADGRL3 mRNA22323515
C487081belinostatbelinostat results in decreased expression of ADGRL3 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ADGRL3 mRNA21569818
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ADGRL3 mRNA22610609
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ADGRL3 mRNA22300585
C006780bisphenol Abisphenol A affects the expression of ADGRL3 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of ADGRL3 promoter22457795
D002737ChloropreneChloroprene results in increased expression of ADGRL3 mRNA23125180
D003042CocaineCocaine affects the expression of ADGRL3 mRNA20187946
D016572CyclosporineCyclosporine results in decreased expression of ADGRL3 mRNA20106945
D019422Dietary SucroseDietary Sucrose results in increased expression of ADGRL3 mRNA26033743
C118739entinostatentinostat results in decreased expression of ADGRL3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of ADGRL3 mRNA26865667
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of ADGRL3 mRNA15901920
D019833GenisteinGenistein results in decreased expression of ADGRL3 mRNA26865667
D005839GentamicinsGentamicins results in decreased expression of ADGRL3 mRNA22061828
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ADGRL3 mRNA26752646
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ADGRL3 mRNA"20188158
C008493methylselenic acidmethylselenic acid results in increased expression of ADGRL3 mRNA18548127
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of ADGRL3 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of ADGRL3 mRNA"25554681
D009532NickelNickel results in decreased expression of ADGRL3 mRNA24768652|2558310
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of ADGRL3 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of ADGRL3 mRNA20813756
D011192Potassium DichromatePotassium Dichromate affects the expression of ADGRL3 mRNA23608068
D011441PropylthiouracilPropylthiouracil affects the expression of ADGRL3 mRNA24780913
C502851quinocetonequinocetone results in increased expression of ADGRL3 mRNA27046791
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ADGRL3 mRNA25895662
D012834SilverSilver results in decreased expression of ADGRL3 mRNA27131904
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ADGRL3 mRNA19465110
D013849ThimerosalThimerosal results in increased expression of ADGRL3 mRNA27188386
C009495titanium dioxidetitanium dioxide affects the expression of ADGRL3 mRNA23557971
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of ADGRL3 mRNA20133372
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of ADGRL3 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ADGRL3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of ADGRL3 mRNA23179753|2627250
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of ADGRL3 mRNA26272509|2718838

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001965G-protein alpha-subunit binding-IBA21873635  
GO:0004930G-protein coupled receptor activity-IBA21873635  
GO:0004930G-protein coupled receptor activity-NAS10994649  
GO:0005509calcium ion binding-IDA26235030  
GO:0005515protein binding-IPI26235030  
GO:0030246carbohydrate binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001764neuron migration-ISS-  
GO:0007166cell surface receptor signaling pathway-IEA-  
GO:0007186G-protein coupled receptor signaling pathway-NAS10994649  
GO:0007416synapse assembly-IBA21873635  
GO:0007416synapse assembly-ISS-  
GO:0007420brain development-IBA21873635  
GO:0031987locomotion involved in locomotory behavior-IEA-  
GO:0042220response to cocaine-IEA-  
GO:0051965positive regulation of synapse assembly-IEA-  
GO:0098742cell-cell adhesion via plasma-membrane adhesion molecules-IBA21873635  
GO:0098742cell-cell adhesion via plasma-membrane adhesion molecules-IDA26235030  
GO ID GO Term Qualifier Evidence PubMed
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-IDA26235030  
GO:0005911cell-cell junction-IBA21873635  
GO:0005911cell-cell junction-ISS-  
GO:0016021integral component of membrane-NAS10994649  
GO:0030424axon-IBA21873635  
GO:0030424axon-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal